Weight Loss Injections: What You Need to Know, From Costs to Alternatives
Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...
Novo Nordisk: Be Greedy When Others Are Fearful
Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...
Daily2d
Combining GLP-1 Therapy with FreeStyle Libre Yields Superior Glycemic Control in Type 2 Diabetes Patients: Study
Further analysis showed that the combination of GLP-1+FSL was associated with greater HbA1c reductions across various ...
New guidelines for treatment of Type 2 diabetes from International Diabetes Federation soon
IDF creating new Type 2 diabetes guidelines with global experts, focusing on patient-centered care and global accessibility.
Endocrinology Advisor3d
GLP-1 Drug Shortages: How Do They Affect Patients With Diabetes?
While older medications for diabetes such as insulin and sulfonylureas predispose to weight gain, GLP-1 receptor agonists ...
MibolsilloUSA on MSN3d
Medicaid coverage for GLP-1 obesity drugs
Only 13 states currently allow Medicaid to cover GLP-1 agonist drugs for obesity treatment, highlighting a significant gap in ...
Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study
Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery - Observed weight loss was 17% at 28 days, a 25% ...
FiercePharma4d
After Lilly's GLP-1 sales fumble, Novo reports mixed results on Ozempic, Wegovy
Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...
Investigating the effect of treatment with GLP-1 receptor agonists on muscle mass
Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic ...